若生智能
Drug Database
ME

measles vaccine (live-attenuated)

✓ Approved

Beijing Tiantan Biological Products · 疫苗 · 疫苗

什么是 measles vaccine (live-attenuated)？

measles vaccine (live-attenuated) 是一种疫苗，由Beijing Tiantan Biological Products研发。该药已获批，用于治疗相关适应症，给药途径：Unknown。

药物档案

公司Beijing Tiantan Biological Products
药物类别疫苗, 大分子
给药途径Unknown
状态Approved
来源： ClinicalTrials.gov, Beijing Tiantan Biological Products

治疗适应症

measles vaccine (live-attenuated) 针对 1 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Infections and infestationsMeasles✓ Approved

相关研究文献

PubMedOpen forum infectious diseases2026-08-04

Measles in Ugandan Children Under 18 Months of Age: A Retrospective Study of Case-based Surveillance, 2018-2024.

Businge Gerald Bright GB, Mupere Ezekiel E, Gyasi Samuel Ofori SO, Le Doare Kirsty K et al.

Measles remains a significant public health threat in Uganda, with regular outbreaks. The current national immunization schedule offers the first measles-containing vaccine dose (MCV) at 9 months, and a second dose at 18 months. We investigated the epidemiology of measles in Ugandan children aged 18 months and younger. We analyzed the national measles surveillance data from 2018 to the first quarter (Q1) of 2024, probing the demographic and geographic distribution. We categorized children as under 6 months, 6 to under 9 months, and 9-18 months. Suspected measles cases were classified as clinical, epidemiologically linked, laboratory-confirmed or discarded (not measles). 1316/2274 (57.9%) of the suspected cases were diagnosed with measles. One hundred and forty-nine cases (11.3%; 95% CI: 9.7-13.0) were aged under 6 months, 390 (29.6%; 27.0-32.0) 6 to under 9 months, and 777 (59.0%; 56.0-62.0) 9-18 months. 717/1208 (59.4%; 57.0-62.0) of vaccine-eligible children, with a captured vaccination history, had received at least 1 dose of MCV. 59.5% (95%CI: 55.0-63.0) of measles cases were unvaccinated vaccine-eligible children. Several districts did not achieve the WHO-recommended measles surveillance threshold of at least 2 discarded cases per 100 000 population. Most measles cases among Ugandan children ≤18 months are unvaccinated. Infants nine to 18 months old comprise most of the measles cases (59.0%; 777/1316). To achieve better control of measles transmission, review of the current vaccination policies with strengthened vaccination and surveillance systems are recommended.

PMID 42549252
阅读全文 →
PubMedOpen forum infectious diseases2026-08-04

Live Respiratory Syncytial Virus Vaccine D46/cp/ΔM2-2 Is Overattenuated in RSV-Seronegative Children.

Karron Ruth A RA, Woods Suzanne S, Wanionek Kimberli K, Oliva Jennifer J et al.

The intranasal respiratory syncytial virus (RSV) vaccine D46/cp/ΔM2-2 is attenuated by deletion of the RSV RNA synthesis factor M2-2 and 5 cold-passage amino acid mutations. D46/cp/ΔM2-2 was safe but overattenuated in 12- to 59-month-old RSV-seropositive children (dose: 106 plaque-forming units [PFU]) and 6- to 24-month-old RSV-seronegative children (dose: 105 PFU). Clinical Trials Registration. ClinicalTrials.gov Number . NCT02601612.

PMID 42549136
阅读全文 →
PubMedIranian journal of public health2026-08-04

Examination of the Publication Quality of Abstracts of Systematic Reviews and Meta-Analyses on Measles, Published between 2009-2023 and Indexed in the PubMed Article Database.

Kara Seyma Aliye SA, Cakir Banu B

Measles, a highly contagious, yet vaccine-preventable disease, is currently experiencing a notable resurge in numbers, in developing countries. With limited reading time, physicians often rely on structured summaries, and well-prepared abstracts can encourage them to read the full article, facilitating patient care. We aimed to examine the reporting quality of article abstracts about measles. Indirectly/directly address measles and its vaccine, scrutinizing on systematic reviews and meta-analyses published from 2009 to the present, and indexed in the open-access PubMed article database. With the widespread use of abstract checklists like PRISMA-A in reading systematic reviews and meta-analyses, the message intended to be conveyed can be adequately delivered to the reader by abstracts only, respecting standard rules and requirements for reporting. We used a scoring system for compliance with PRISMA-A checklist in reading measles-related reviews published over the last 15 years. On average, the abstracts were "very highly" compliant with the expected reporting criteria: The year of publication (with 2020 as the timepoint) did not make any difference in reporting quality, but structured abstract were significantly more likely to convey their message in an "expected" manner, based on PRISMA-A criteria. Using standard guidelines in evaluating reporting quality of different publications and emphasizing its importance for the writers and readers, alike, will be encouraging for improved presentation of original/filtered research results, with the goal of conveying valid and reliable health-related information, in a time-efficient way.

PMID 42548955
阅读全文 →
PubMedVaccine2026-08-04

Advances in clinical immunogenicity evaluation of influenza vaccines.

Xu Nan N, Wang Liangliang L, Zhao Chunhui C, Shen Yanru Y et al.

Influenza vaccination is an effective intervention for preventing severe influenza, and assessing its immunogenicity is a critical step in determining vaccine protective efficacy. With the widespread use of influenza vaccines-including split-virion, subunit, recombinant protein, and live attenuated formulations-methods for evaluating immunogenicity have grown increasingly diverse and complex. This article systematically examines the advantages and limitations of various immunogenicity assessment approaches for influenza vaccines. It draws upon multidimensional evaluation frameworks covering humoral, cellular, and mucosal immunity, incorporating analytical techniques such as hemagglutination inhibition assays, microneutralization assays, enzyme-linked immunosorbent assays, mucosal secretory IgA detection, enzyme-linked immunospot assays, and flow cytometry. Furthermore, clinical challenge trials evaluations play an essential role in elucidating the relationship between immunogenicity and protective efficacy. This paper aims to establish a systematic and comprehensive reference framework for the development and immunogenicity evaluation of influenza vaccines, thereby advancing vaccine design and the prediction of protective outcomes toward greater precision.

PMID 42546636
阅读全文 →
PubMedPoultry science2026-08-04

Nanotechnology-Enabled Approaches in Poultry Coccidiosis Management: Advances, Challenges, and Future Perspectives.

El-Shall Nahed A NA, Hassanien Hesham A HA, Shehab-El-Deen Mohamed M, Idan Frank F et al.

Avian coccidiosis, a disease resulting from infection by various Eimeria species, is a major constraint to global poultry production, causing considerable economic losses and affecting animal performance. Traditional approaches to coccidiosis control, such as anticoccidials and live vaccines, face limitations in their use owing to resistance, safety concerns, and species-specific immunity. In this regard, subunit, DNA, and multi-epitope vaccines have been tested against coccidiosis, but their efficacy is hindered by the instability of the vaccine antigens and a lack of cross-protection. However, recent advances in nanotechnology may provide a solution to the limitations associated with traditional approaches to coccidiosis control. For instance, nanoparticles may improve vaccine efficacy by stabilizing vaccine antigens, facilitating their delivery, and modulating immune responses. Furthermore, various nanoparticle therapeutics, such as plant-based and metal-based nanoparticles, and nano-encapsulated anticoccidials, may also reduce oocyst shedding and improve gut health and antioxidant status. Although this is a positive step in coccidiosis control, there are many issues that need to be resolved. This review provides a critical analysis of recent advances in various aspects of nanotechnology-based approaches to coccidiosis control, their potential, and research gaps.

PMID 42546433
阅读全文 →
PubMedThe Lancet. Infectious diseases2026-08-04

Efficacy, immunogenicity, and safety of the 9-valent human papillomavirus vaccine in males aged 16-26 years in Japan: a randomised, double-blind, placebo-controlled trial.

Hisamoto Koji K, Yamanaka Masaki M, Nomura Masayasu M, Kanno Nobufumi N et al.

Efficacy of the nine-valent human papillomavirus (9vHPV; HPV6, 11, 16, 18, 31, 33, 45, 52, and 58) vaccine was shown in females and inferred for males through immunobridging. We evaluated the efficacy of the 9vHPV vaccine in males aged 16-26 years. This randomised, double-blind, placebo-controlled, efficacy, immunogenicity, and safety phase 3 trial was conducted at 22 clinical research, hospital, medical, or treatment sites in Japan, with masking of investigators, sponsor personnel, and participants. Healthy males aged 16-26 years with no history of human papillomavirus (HPV)-related lesions and no previous HPV vaccination were randomly assigned (1:1) centrally, using permutated blocks (block sizes of four), to receive three intramuscular injections of the 9vHPV vaccine or placebo (saline) at day 1, month 2, and month 6. The primary and secondary efficacy endpoints were the combined incidences of 6-month anogenital persistent infection related to HPV6, 11, 16, and 18 and HPV31, 33, 45, 52, and 58. Anogenital swabs and external genital tissue samples were tested for the presence of HPV DNA. Tissue samples were adjudicated for histopathology diagnosis. The primary and secondary efficacy evaluations were tested for superiority with a margin of 0% in the per-protocol population. Another secondary endpoint was antibody responses to each vaccine-targeted HPV type at month 7; immunogenicity analyses were conducted in the per-protocol immunogenicity population. Safety was assessed in participants who received at least one dose of vaccine or placebo. This study is registered with ClinicalTrials.gov (NCT04635423) and is completed. Between Nov 30, 2020, and Dec 25, 2021, 1059 participants were enrolled and randomly assigned to receive the 9vHPV vaccine (n=529) or placebo (n=530). Vaccine efficacy for the primary and secondary endpoints was 89·3% (95% CI 55·4-98·2; p=0·0002) and 63·5% (2·7-86·0; p=0·023), respectively, in the initial efficacy analysis based on a visit cutoff date of Dec 29, 2023, and 91·6% (67·7-98·6) and 72·9% (38·7-89·3) in the end-of-study efficacy analysis based on a visit cutoff date of July 16, 2024. Seroconversion rates were greater than 98% for each vaccine-targeted HPV type. Injection-site adverse events were reported in 370 (70%) of 529 9vHPV vaccine recipients and 162 (31%) of 530 placebo recipients, and vaccine-related systemic adverse events in 58 (11%) vaccine recipients and 52 (10%) placebo recipients; most cases were mild or moderate. No deaths, vaccine-related serious adverse events, or discontinuations due to adverse events were reported. The 9vHPV vaccine prevents anogenital persistent infection related to vaccine-targeted HPV types in males and has an acceptable safety profile. These findings support the use of the 9vHPV vaccine in males to prevent HPV-related anogenital diseases. Merck Sharp & Dohme. For the Japanese translation of the abstract see Supplementary Material section.

PMID 42546724
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多measles vaccine (live-attenuated)